Literature DB >> 6684412

High-pressure liquid chromatographic analysis of aztreonam in sera and urine.

F G Pilkiewicz, B J Remsburg, S M Fisher, R B Sykes.   

Abstract

Aztreonam (SQ 26,776) is a new synthetic monocyclic beta-lactam antibiotic which is specifically active against aerobic gram-negative bacteria. High-pressure liquid chromatographic (HPLC) systems were developed for the quantitative analysis of aztreonam in human, monkey, rat, mouse, and rabbit sera and urine. The HPLC conditions employed for these analyses were a muBondapak C18 column, a mobile phase made up of 0.005 M tetrabutylammonium hydrogen sulfate at pH 3.0 and acetonitrile or methanol, UV detection at 293 nm, and a flow rate of 2.0 ml/min. For human sera and urine, the mobile phase was 80% 0.005 M tetrabutylammonium hydrogen sulfate-0.005M (NH4)2SO4 and 20% acetonitrile (vol/vol). For the range of sera and urine, HPLC analyses were shown to have excellent detector linearity of aztreonam over a concentration range of 1.0 mg/ml to 0.5 microgram/ml. Correlation coefficients for plots of aztreonam peak area versus its concentration were greater than or equal to 0.990. The detection limit of aztreonam was 1.0 micrograms/ml in sera and 5.0 micrograms/ml in urine. HPLC and microbiological assays of aztreonam in human sera and urine were in good agreement.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6684412      PMCID: PMC184982          DOI: 10.1128/AAC.23.6.852

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  The determination of cephradine and cephalexin by reverse phase high-performance liquid chromatography.

Authors:  M A Carrol; E R White; Z Jancsik; J E Zarembo
Journal:  J Antibiot (Tokyo)       Date:  1977-05       Impact factor: 2.649

Review 2.  Analysis of drugs and their metabolites by high-performance liquid chromatography. A review.

Authors:  B B Wheals; I Jane
Journal:  Analyst       Date:  1977-09       Impact factor: 4.616

3.  Pharmacokinetics of the monobactam SQ 26,776 after single intravenous doses in healthy subjects.

Authors:  E A Swabb; M A Leitz; F G Pilkiewicz; A A Sugerman
Journal:  J Antimicrob Chemother       Date:  1981-12       Impact factor: 5.790

4.  In-vivo properties of SQ 26,776.

Authors:  D P Bonner; R R Whitney; C O Baughn; B H Miller; S J Olsen; R B Sykes
Journal:  J Antimicrob Chemother       Date:  1981-12       Impact factor: 5.790

5.  High speed liquid chromatographic determination of cephalexin in human plasma and urine.

Authors:  T Nakagawa; J Haginaka; K Yamaoka; T Uno
Journal:  J Antibiot (Tokyo)       Date:  1978-08       Impact factor: 2.649

6.  Monocyclic beta-lactam antibiotics produced by bacteria.

Authors:  R B Sykes; C M Cimarusti; D P Bonner; K Bush; D M Floyd; N H Georgopapadakou; W M Koster; W C Liu; W L Parker; P A Principe; M L Rathnum; W A Slusarchyk; W H Trejo; J S Wells
Journal:  Nature       Date:  1981-06-11       Impact factor: 49.962

Review 7.  High-pressure liquid chromatography for quantitation of antimicrobial agents.

Authors:  T T Yoshikawa; S K Maitra; M C Schotz; L B Guze
Journal:  Rev Infect Dis       Date:  1980 Mar-Apr

8.  Reverse phase high speed liquid chromatography of antibiotics. III. Use of ultra high performance columns and ion-pairing techniques.

Authors:  E R White; J E Zarembo
Journal:  J Antibiot (Tokyo)       Date:  1981-07       Impact factor: 2.649

9.  Reverse phase high speed liquid chromatography of antibiotics. II. Use of high efficiency small particle columns.

Authors:  E R White; M A Carroll; J E Zarembo
Journal:  J Antibiot (Tokyo)       Date:  1977-10       Impact factor: 2.649

10.  Azthreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic gram-negative bacteria.

Authors:  R B Sykes; D P Bonner; K Bush; N H Georgopapadakou
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

View more
  10 in total

1.  Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers.

Authors:  Jared L Crandon; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

2.  Clinical pharmacokinetics of aztreonam in cancer patients.

Authors:  P G Jones; G P Bodey; E A Swabb; D H Ho; V Fainstein; J Pasternak
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

3.  Aztreonam pharmacokinetics in burn patients.

Authors:  L V Friedrich; R L White; M B Kays; D M Brundage; D Yarbrough
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

4.  Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units).

Authors:  Eric Viaene; Hugues Chanteux; Hélène Servais; Marie-Paule Mingeot-Leclercq; Paul M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

5.  Aztreonam, cefoperazone, and gentamicin in the treatment of experimental Enterobacter aerogenes endocarditis in rabbits.

Authors:  W D Kobasa; D Kaye
Journal:  Antimicrob Agents Chemother       Date:  1983-09       Impact factor: 5.191

6.  Aztreonam concentrations in human tissues obtained during thoracic and gynecologic surgery.

Authors:  T R Beam; R P Galask; L T Friedhoff; T B Platt; M A Leitz
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

7.  Aztreonam penetration into synovial fluid and bone.

Authors:  C M MacLeod; E A Bartley; J O Galante; L T Friedhoff; R Dhruv
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

8.  Pharmacokinetics of aztreonam in patients with gram-negative infections.

Authors:  D M Janicke; R F Cafarell; S W Parker; M A Apicella; W J Jusko
Journal:  Antimicrob Agents Chemother       Date:  1985-01       Impact factor: 5.191

9.  Comparative pharmacokinetics of carumonam and aztreonam in mice, rats, rabbits, dogs, and cynomolgus monkeys.

Authors:  Y Kita; T Fugono; A Imada
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

10.  Aztreonam concentration in abdominal tissues and bile.

Authors:  R E Condon; L T Friedhoff; C E Edmiston; B Levinson
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.